# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of...
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...
The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of...
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...
ENSC: 92% | Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Ne...
"We are appreciative of the guidance provided by the FDA to help us properly position PF614 as we progress through clinical...
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC), a clinical-stage biotech company applyin...